Institutional shares held 112 Million
1M calls
668K puts
Total value of holdings $310M
$2.78M calls
$1.86M puts
Market Cap $347M
124,986,000 Shares Out.
Institutional ownership 89.32%
# of Institutions 100


Latest Institutional Activity in MREO

Top Purchases

Q1 2025
Janus Henderson Group PLC Shares Held: 22.7M ($63.2M)
Q1 2025
Frazier Life Sciences Management, L.P. Shares Held: 7.82M ($21.7M)
Q1 2025
Abrdn PLC Shares Held: 2.19M ($6.08M)
Q1 2025
Schonfeld Strategic Advisors LLC Shares Held: 1.59M ($4.42M)
Q1 2025
Ubs Asset Management Americas Inc Shares Held: 1.57M ($4.36M)

Top Sells

Q1 2025
Adage Capital Partners Gp, L.L.C. Shares Held: 1.7M ($4.73M)
Q1 2025
Millennium Management LLC Shares Held: 394K ($1.1M)
Q1 2025
Rock Springs Capital Management LP Shares Held: 6.68M ($18.6M)
Q1 2025
Ubs Group Ag Shares Held: 932K ($2.59M)
Q1 2025
Morgan Stanley Shares Held: 2.18M ($6.06M)

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.


Insider Transactions at MREO

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
673K Shares
From 6 Insiders
Exercise of conversion of derivative security 673K shares
Sell / Disposition
417K Shares
From 6 Insiders
Open market or private sale 417K shares

Track Institutional and Insider Activities on MREO

Follow Mereo Biopharma Group plc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MREO shares.

Notify only if

Insider Trading

Get notified when an Mereo Biopharma Group PLC insider buys or sells MREO shares.

Notify only if

News

Receive news related to Mereo Biopharma Group plc

Track Activities on MREO